Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Invesco S&P 500 Momentum ETF (SPMO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Invesco S&P 500 Momentum ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.69 (market cap $29.60B), while Invesco S&P 500 Momentum ETF trades at $151.74. The key difference: Invesco S&P 500 Momentum ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | SPMO | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $491.22 | $161.66 |
52-Week Low | $205.48 | $107.84 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
SPMO, trading at $151.89 with a 2.15% daily gain, shows strong momentum-driven performance, supported by a bullish technical signal from moving averages and positive media coverage highlighting its 26% returns year-to-date. The ETF's concentrated, tech-heavy portfolio leverages AI growth trends, though key financial ratios like P/E and P/S are not disclosed in the provided data. A dividend of $0.25 is scheduled for June 2026, adding income potential for investors.
The outlook for SPMO remains favorable due to sustained momentum factor strength and institutional interest, but risks include high volatility from sector concentration and potential downturns during market rotations. Investors should weigh the ETF's cost efficiency and historical outperformance against its exposure to tech sector swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →
